Menu Back toUsing Real-World Data in Single-Arm Trials: When It’s Done, Why It’s Done, How It’s Done
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA 2021 Global Annual Meeting
Using Real-World Data in Single-Arm Trials: When It’s Done, Why It’s Done, How It’s Done
David Thompson, PhD
- Chief Executive Officer for Health Evidence and Access
- OPEN Health, United States
As real-world data increasingly provide synthetic controls in single-arm drug registration studies, terminology and insights have evolved. The structured, multistep assessment process described addresses why, when, and where to use new approaches.
Learning Objective : Describe fundamentals of synthetic control arms and real-world data integration into clinical trials; Discuss relevant key terminology; Evaluate feasibility of using an external control arm in a clinical trial; Identify how to weigh pros and cons of historical versus concurrent control arm data; Identify potential external sources for control populations.
Application of Real-World Evidence to Support Breakthrough Drug Development
Mark Stewart, PhD
- Vice President, Science Policy
- Friends of Cancer Research, United States
Toward Greater Use of RWD-Based External Controls in Regulatory Decisions: Design and Methods Considerations
Khaled Sarsour, PhD, MPH
- Global Head, RWD Hematology-Oncology
- Genentech, A Member of the Roche Group, United States
Craig White, PhD
- Senior Vice President and Managing Director, Outcomes Science
- Concertai, United States